FDA panel endorses Moderna’s next-gen mRNA flu shot for older adults

An FDA advisory panel unanimously recommended Moderna’s mRNA flu vaccine (mFlusiva) for adults 50 and older, approving it for two age groups (50–64 and 65+), with a requirement for an additional post‑market trial in the older cohort. In trials, the shot was about 27% more effective than standard flu vaccines. If FDA and then CDC sign off, it could become the first mRNA influenza vaccine, and its flexible, quickly updated design could help match circulating strains, though final timelines and access this fall remain uncertain amid regulatory and political considerations.